Adverse Events in Medication Treatment-Naïve Children with Attention-Deficit/Hyperactivity Disorder: Results from a Small, Controlled Trial of Lisdexamfetamine Dimesylate
Authors:
- 1 April 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 22 (2) , 149-156
Abstract
Objective: To evaluate the type, frequency, duration, and severity of treatment emergent adverse events (TEAEs) of the prodrug lisdexamfetamine dimesylate (LDX) in children with and without previous exposure to stimulant medication in the treatment of attention-deficit/hyperactivity disorder (ADHD). Methods: This single-blind, modified laboratory school study used open-label, dose optimization of children aged 6–12 years. LDX, initiated at 30 mg, was dose titrated in 20 mg increments to a possible 70 mg over 4–5 weeks. Safety was assessed using adverse effects and LDX levels. Results: Twenty-eight subjects enrolled in the study, with 27 safety protocol completers ( n =14 previous stimulant exposure; n =13 stimulant naïve). The stimulant-naïve group reported more trouble sleeping, stomach pain, and hyperfocus, but only previous-exposure subjects experienced dizziness. Previous-exposure subjects showed trends of more decreased appetite, less talkativeness, and less lip sucking. There were no differences in the mean duration of TEAEs. The epidemiological method of percent person-weeks applied to ADHD treatment offers a novel approach to interpreting the pattern of TEAEs. Conclusion: LDX reduced the core symptoms of ADHD with more severe adverse events in stimulant-naïve than previous-exposure subjects. Future controlled studies with larger samples should address the impact of previous stimulant exposure on other ADHD treatments.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the dayChild and Adolescent Psychiatry and Mental Health, 2010
- Predictors of switching antipsychotic medications in the treatment of schizophreniaBMC Psychiatry, 2010
- Does Prior Exposure to Stimulants in Children with ADHD Impact Cardiovascular Parameters from Lisdexamfetamine Dimesylate?Postgraduate Medicine, 2010
- Cardiovascular Effects of Medications for the Treatment of Attention-Deficit Hyperactivity DisorderPediatric Drugs, 2010
- A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorderChild and Adolescent Psychiatry and Mental Health, 2009
- American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHDJournal of Developmental & Behavioral Pediatrics, 2008
- Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapyBritish Journal of Pharmacology, 2006
- Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?BMJ, 2001
- General Versus Systematic Inquiry about Emergent Clinical Events with SAFTEEJournal of Clinical Psychopharmacology, 1992
- The pharmacology of Parkinson's disease: Basic aspects and recent advancesCellular and Molecular Life Sciences, 1984